| EVOTF Stock | | | USD 6.77 0.00 0.00% |
Executive
Dr. Cord Dohrmann has served as Chief Scientific Officer and Member of the Management Board at Evotec AG since September 1, 2010. Dr. Dohrmann has spent over 20 years in biomedical research at academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tuebingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the MaxPlanck Institute in Tuebingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a startup to an internationally recognized metabolic disease company with a pipeline of innovative preclinical and clinical products for the treatment of diabetes and related disorders since 2010.
| Age | 59 |
| Tenure | 14 years |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Dohrmann was advising the European Commission, the MaxPlanckInstitute as well as VC firms and authored and coauthored a number of publications and patents. Since December 2016, Dr. Dohrmann was serving as member of the Supervisory Board of Eternygen GmbH. In June 2017, he became a member of the Supervisory Board of Facio Therapies BV.
Evotec SE Management Efficiency
Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.
Evotec SE has accumulated 326.34
M in total debt with debt to equity ratio
(D/E) of 0.38, which is about average as compared to similar companies. Evotec SE has a current ratio of 3.5, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Evotec SE until it has trouble settling it off, either with new capital or with free cash flow. So, Evotec SE's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evotec SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evotec to invest in growth at high rates of return. When we think about Evotec SE's use of debt, we should always consider it together with cash and equity.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. EVOTEC SE operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4521 people. Evotec SE [EVOTF] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Evotec SE Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers, Chief Board | |
| Volker Braun, VP ESG | |
| Cord Dohrmann, Chief Scientific Officer and Member of Management Board | |
| Enno Spillner, CFO, Member of the Management Board | |
| Monika Conradt, Global HR | |
| Gabriele Hansen, Vice President Corporate Communications & Investor Relations | |
| Christian Dargel, EVP Compliance | |
| MBA MBA, Chairman CEO | |
| Craig Johnstone, COO, Member of the Management Board | |
| Anja Bosler, Principal Accounting | |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Evotec Pink Sheet
Evotec SE financial ratios help investors to determine whether Evotec Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evotec with respect to the benefits of owning Evotec SE security.